Managers / Q4 2018 · view latest →
SV Health Investors, LLC
CIK 0001587143 · ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON, MA, 02108 · 617-367-8100
Summary
Sv Health Investors, LLC reported $162M in U.S.-listed holdings across 9 positions for Q4 2018.
The portfolio is heavily concentrated: Kalvista Pharmaceuticals alone accounts for 31.0% of reported value.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 58.4% · $95M
- Other · 41.6% · $68M
Quarter-over-Quarter Changes full breakdown →
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| KALVISTA PHARMACEUTICALS INC | NEW | +2.55M | 2.55M | +$50M | $50M |
| AVROBIO INC | NEW | +2.74M | 2.74M | +$46M | $46M |
| DECIPHERA PHARMACEUTICALS INC | NEW | +1.29M | 1.29M | +$27M | $27M |
| SUTRO BIOPHARMA INC | NEW | +1.82M | 1.82M | +$16M | $16M |
| TRANSENTERIX INC | NEW | +6.63M | 6.63M | +$15M | $15M |
| ARSANIS INC | NEW | +1.87M | 1.87M | +$4M | $4M |
| OCULOCULAR THERAPEUTIX INC | NEW | +628.2K | 628.2K | +$3M | $3M |
| CATABASIS PHARMACEUTICALS IN | NEW | +285.8K | 285.8K | +$1M | $1M |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q4 2018
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | KALVISTA PHARMACEUTICALS INC | COM | 30.98% | $50M | 2.55M |
| 2 | AVROBIO INC | COM | 28.05% | $46M | 2.74M |
| 3 | DECIPHERA PHARMACEUTICALS INC | COM | 16.63% | $27M | 1.29M |
| 4 | SUTRO BIOPHARMA INC | COM | 10.13% | $16M | 1.82M |
| 5 | TRANSENTERIX INC | COM NEW | 9.23% | $15M | 6.63M |
| 6 | ARSANIS INC | COM | 2.67% | $4M | 1.87M |
| 7 | OCULOCULAR THERAPEUTIX INChistory → | COM | 1.54% | $3M | 628.2K |
| 8 | CATABASIS PHARMACEUTICALS IN | COM | 0.77% | $1M | 285.8K |
| 9 | RESHAPE LIFE SCIENCES INC | COM | 0.00% | $0 | 1.1K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2022 | $32M | 4 | Nov 7, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q2 2022 | $44M | 5 | Aug 12, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q1 2022 | $83M | 5 | May 16, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q4 2021 | $155M | 6 | Feb 11, 2022 | 13F-HR | changes · EDGAR ↗ |
| Q3 2021 | $204M | 8 | Nov 15, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q2 2021 | $230M | 7 | Aug 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q1 2021 | $267M | 8 | May 17, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q4 2020 | $208M | 9 | Feb 16, 2021 | 13F-HR | changes · EDGAR ↗ |
| Q3 2020 | $197M | 10 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $144M | 10 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $119M | 10 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $165M | 10 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $142M | 10 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $149M | 9 | Aug 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $170M | 8 | May 15, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q4 2018 | $162M | 9 | Feb 14, 2019 | 13F-HR | changes · EDGAR ↗ |
Other Included Managers
This filing reports holdings on behalf of 4 additional managers.
- SVLSF IV, LLC028-16272
- SV Life Sciences Fund IV (GP), L.P.028-16273
- SVLSF VI, LLC028-19256
- SV Life Sciences Fund VI (GP), L.P.028-19255
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.